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Interleukin-2 (IL-2) is a pleiotropic cytokine that regu-
lates immune cell homeostasis and has been used
to treat a range of disorders including cancer and
autoimmune disease. IL-2 signals via interleukin-2
receptor-b (IL-2Rb):IL-2Rg heterodimers on cells
expressing high (regulatory T cells, Treg) or low
(effector cells) amounts of IL-2Ra (CD25). When
complexed with IL-2, certain anti-cytokine anti-
bodies preferentially stimulate expansion of Treg
(JES6-1) or effector (S4B6) cells, offering a strategy
for targeted disease therapy. We found that JES6-1
sterically blocked the IL-2:IL-2Rb and IL-2:IL-2Rg
interactions, but also allosterically lowered the
IL-2:IL-2Ra affinity through a ‘‘triggered exchange’’
mechanism favoring IL-2Rahi Treg cells, creating a
positive feedback loop for IL-2Rahi cell activation.
Conversely, S4B6 sterically blocked the IL-2:IL-2Ra
interaction, while also conformationally stabilizing
the IL-2:IL-2Rb interaction, thus stimulating all IL-2-
responsive immune cells, particularly IL-2Rbhi
effector cells. These insights provide a molecular
blueprint for engineering selectively potentiating
therapeutic antibodies.
INTRODUCTION
Interleukin-2 (IL-2) is a four-helix bundle cytokine that plays a
critical role in immune cell differentiation, growth, and activity.
IL-2 signals through formation of either a high-affinity quaternary
complex with the interleukin-2 receptor-a (IL-2Ra, CD25), IL-
2Rb, and IL-2Rg chains (Kdz 10 pM) or an intermediate-affinity
ternary complex (Kd z 1 nM) with only the IL-2Rb and IL-2Rg
chains (Wang et al., 2005; Boyman and Sprent, 2012; Liao
et al., 2013). Consequently, expression of the non-signaling IL-
2Ra subunit regulates cytokine sensitivity. IL-2Ra is robustlyexpressed on regulatory T (Treg) cells but is virtually absent
from naive effector cells such as memory phenotype (MP)
CD8+ T cells and natural killer (NK) cells, resulting in differential
responsiveness of these immune cell subsets to IL-2 (Fontenot
et al., 2005; Josefowicz et al., 2012; Malek and Bayer, 2004).
Upon IL-2 complex formation, intracellular Janus kinase (JAK)
proteins constitutively associated with IL-2Rb and IL-2Rg phos-
phorylate tyrosine residues in the receptor intracellular domains,
which recruit and activate signal transducer and activator of
transcription 5 (STAT5) to coordinate immune-related gene
expression programs (Malek, 2008). The IL-2 complex also sig-
nals secondarily through the mitogen-activated protein kinase
(MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways
(Malek, 2008; Taniguchi and Minami, 1993).
IL-2 exerts paradoxical effects on immune cell homeostasis,
promoting activation and proliferation of both immunostimula-
tory effector cells and immunosuppressive Treg cells, and its
vital role in immune regulation has made IL-2 an attractive ther-
apeutic target in a range of immune-linked diseases, both to pro-
mote the immune response (as in cancer and infectious disease)
and to repress the immune response (as in autoimmune disor-
ders and graft-versus-host disease) (Boyman and Sprent,
2012; Brusko et al., 2008; Liao et al., 2013; Waldmann, 2006).
However, the clinical utility of IL-2 has been limited by the multi-
farious nature of its activities, which can thwart efficacy and lead
to toxicity and harmful off-target effects (Boyman et al., 2006b;
Rosenberg, 2012; Shevach, 2012). It would thus be of tremen-
dous therapeutic value to decouple the immunostimulatory and
immunosuppressive activities of IL-2 to cater to particular dis-
ease applications.
One emerging strategy for selectivelymodulating the effects of
IL-2 is development of cytokine-directed antibodies that bias
activity toward specific T cell subsets. Co-administration of anti-
bodies with IL-2 offers important therapeutic advantages such
as prolonged in vivo half-life due to Fc receptor interactions
(Boyman et al., 2006b; Finkelman et al., 1993; Le´tourneau
et al., 2010). Boyman et al. (2006a) established that immunocom-
plexes formed by pre-association of two anti-mouse IL-2 (mIL-2)
antibodies with the cytokine elicit contrasting effects: mIL-
2:JES6-1 immunocomplexes actively induce proliferation ofImmunity 42, 815–825, May 19, 2015 ª2015 Elsevier Inc. 815
Figure 1. Anti-IL-2 Antibodies Bias Cytokine Signaling and Functional Outcomes
(A) Schematic of IL-2 cytokine-receptor quaternary complex formation (top) and regulatory (Treg) versus effector (Eff) immune cell proliferation biases induced by
mIL-2:JES6-1 (middle) and mIL-2:S4B6 (bottom) immunocomplexes.
(legend continued on next page)
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IL-2Rahi cells, preferentially expanded Treg cells over effector
cells, whereas mIL-2:S4B6 immunocomplexes stimulated prolif-
eration of all immune cells, but particularly favored effector cells
(Figure 1A). Subsequent work has validated therapeutic applica-
tions for these two antibodies: JES6-1 immunocomplexes pro-
mote graft tolerance (Park et al., 2010; Webster et al., 2009)
and show efficacy in preclinical models of diabetes (Grinberg-
Bleyer et al., 2010; Tang et al., 2008), and S4B6 immunocom-
plexes exhibit potent anti-tumor activity (Jin et al., 2008; Verdeil
et al., 2008) without inducing toxicity (Krieg et al., 2010). It has
been proposed that biased immunocomplex activity results
from antibody obstruction of specific epitopes on the cytokine,
namely that JES6-1 blocks the IL-2Rb binding site on mIL-2 to
disrupt interaction with IL-2Ralo effector cells whereas S4B6
blocks the mIL-2Ra binding site on mIL-2 to prevent high-affinity
interactions with IL-2Rahi Treg cells (Boyman and Sprent, 2012;
Rojas et al., 2013, 2014). However, in the absence of structural or
molecular characterization, the mechanistic basis for selective
cytokine potentiation remains speculative.
In this report, we have combined crystallographic, biophysi-
cal, and functional data to elucidate the molecular rationale for
antibody-induced bias of cytokine activity. We show that
JES6-1 and S4B6 exerted complex steric and allosteric effects
on IL-2 to differentially activate immune cell subsets based on
their IL-2 receptor surface expression profiles and that this
biased activation was further propagated through transcriptional
feedback. Our findings provide a direct link between the molec-
ular interactions of cytokine-antibody complexes and their
unique functional outcomes. These mechanistic insights into im-
mune cell subset-specific potentiation establish a paradigm for
antibody-mediated modulation of IL-2 behavior that will inform
the design of enhanced cytokine-targeted therapeutics.
RESULTS
IL-2-Targeted Antibodies Inhibit Cytokine Signaling to
Induce Biased T Cell Subset Proliferation
To elucidate the molecular properties of JES6-1 and S4B6 that
contribute to their functional behavior, we probed antibody
effects on mIL-2-induced signaling in IL-2Ra and IL-2Ra+ hu-
man YT-1 NK cells as a surrogate for their effects on IL-2Ralo
versus IL-2Rahi immune cell subsets. Cross-reactivity between
mouse and human receptors (Figure S1A) enabled interrogation
of murine cytokine signaling on human cells, although its
potency was reduced compared to the human cytokine due to
its weaker affinity for the human IL-2 receptor subunits. On IL-
2Ra cells, JES6-1 abolished IL-2-mediated STAT5 activation.
S4B6 slightly inhibited activation, which was unexpected but is(B) STAT5 phosphorylation response to mIL-2 or mIL-2:antibody immunocompl
maximal effective concentrations (EC50s) for STAT5 activation are indicated. Dat
(C) C57BL/6 mouse spleen effector cell:Treg cell ratios after mIL-2 or immunoco
(D) Treg cell expansion in BALB/cmouse spleens in response to anti-mIL-2Ra anti
cells that are IL-2Ra+. Bottom plots show only CD4+ cells and the percentages
treatment condition.
(E) Colon histopathology of colitis-induced BALB/c mice pretreated with anti-mI
(F) Evaluation of disease progression indicators for treated mice. *p < 0.05 by S
disease activity score). All error bars indicate SD.
Also see Figure S1.rationalized by structural and mechanistic experiments pre-
sented later in this report. On IL-2Ra+ cells, both JES6-1 and
S4B6 greatly reduced IL-2 potency (Figure 1B). Importantly,
IL-2 activity was greater on IL-2Ra+ cells in the presence of
JES6-1 and greater on IL-2Ra cells in the presence of S4B6,
consistent with preferential activation of IL-2Rahi Treg cells and
IL-2Ralo effector cells, respectively. STAT5 signaling modulation
was independent of antibody bivalency, as shown by the fact
that the single-chain variable fragment (scFv) of JES6-1 and
the Fab fragment of S4B6 induced the same qualitative effects
as their corresponding antibodies, albeit with attenuated po-
tency (Figure S1B), presumably a consequence of the >25-fold
higher apparent affinity of the bivalent versus monovalent anti-
bodies (Figure S1C).
In vitro IL-2Ra expression-based signaling blockade trans-
lated into in vivo skewing of the effector cell:Treg cell ratio.
IL-2Rahi Treg cells were enriched 3-fold after mIL-2:JES6-1
immunocomplex injection into mice and, conversely, IL-2Ralo
MP CD8+ T cells and NK cells were enriched 5-fold after
mIL-2:S4B6 immunocomplex injection compared to unbound
cytokine administration (Figure 1C).
JES6-1 Induces Potentiation of Treg Cell Growth and
Inhibits Autoimmune Disease Progression in Mice
Given that the effector cell bias induced by S4B6 has promising
implications for cancer treatment (Jin et al., 2008; Krieg et al.,
2010; Verdeil et al., 2008), we sought to explore the therapeutic
potential of the Treg cell bias induced by JES6-1 in the context of
autoimmunity by using a mouse model of inflammatory bowel
disease (IBD). We assessed the ability of mIL-2:JES6-1 com-
plexes to prevent disease in the dextran sodium sulfate (DSS)
colitis model. Prior to DSS exposure, mice were treated with a
vehicle control, a Treg-cell-depleting anti-mIL-2Ra antibody,
or mIL-2:JES6-1 complexes, which enriched relative Treg cell
(IL-2Ra+Foxp3+) numbers 10-fold (Figure 1D). We also ob-
served 3-fold enrichment of IL-2Ra+Foxp3 cells, consistent
with previous reports that JES6-1-containing immunocom-
plexes induce expansion of IL-2Ra-expressing activated
T cells (Castro et al., 2012; Tomala et al., 2009). One week after
colitis induction, we observed that mIL-2:JES6-1 immunocom-
plex pretreatment yielded significant improvements in colon
length and histopathology and drastically reduced disease activ-
ity, with treated mice exhibiting similar characteristics to those in
which disease was not induced (Figures 1E and 1F). Notably,
mice treated with PBS exhibited nearly identical disease severity
to Treg-cell-depleted mice (anti-mIL-2Ra antibody cohort), indi-
cating that in the absence of expansion, background amounts of
Treg cells in these mice provide no protective advantage. Inex treatment in IL-2Ra (top) or IL-2Ra+ (bottom) YT-1 human NK cells. Half-
a are representative of three independent experiments.
mplex treatment. Data are representative of two independent experiments.
body (Ab) ormIL-2:JES6-1 treatment. Top plots display the percentage of CD4+
of Treg (IL-2Ra+FoxP3+) cells and IL-2Ra+FoxP3 cells are shown for each
L-2Ra Ab or mIL-2:JES6-1.
tudent’s t test (colon length) or Mann-Whitney U test (histological grade and
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Figure 2. mIL-2:JES6-1 and mIL-2:S4B6
Complex Structures Reveal Basis for
Competitive Binding between Anti-IL-2
Antibodies and IL-2 Receptor
(A) Orthosteric views of the hIL-2 cytokine-recep-
tor quaternary complex (PDB: 2B5I) comprised of
hIL-2 (pink), IL-2Ra (cyan), IL-2Rb (navy), and IL-
2Rg (gold).
(B) Overlay of the mIL-2:JES6-1 and mIL-2:S4B6
complex structures on the hIL-2 quaternary com-
plex. Both JES6-1-bound mIL-2 (dark gray) and
S4B6-bound mIL-2 (light gray) are presented, with
the JES6-1 variable heavy (VH, blue) and light (VL,
magenta) and the S4B6 VH (orange) and VL
(green) chains shown as surface representations.
Crystallographic statistics for mIL-2:antibody
complexes are provided in Table S1.
(C) ‘‘Top-down’’ (left) and ‘‘bottom-up’’ (right)
views of JES6-1-bound mIL-2 (dark gray) and
S4B6-bound mIL-2 (light gray) with the predicted
binding epitopes of IL-2Ra (cyan), IL-2Rb (navy),
IL-2Rg (gold), JES6-1 (blue), and S4B6 (orange) on
the mIL-2 cytokine shaded. Residues shared be-
tween the mIL-2:antibody and the mIL-2:IL-2Ra,
mIL-2:IL-2Rb, or mIL-2:IL-2Rg interfaces are
colored red. Venn diagrams at bottom indicate the
relative extent of overlap between the antibody
and receptor epitopes.
Also see Figure S2.combination with our signaling and proliferation studies, this
mouse model demonstrates a potential therapeutic application
of selective immune cell subset stimulation.
mIL-2:JES6-1 and mIL-2:S4B6 Complex Structures
Reveal Contrasting IL-2 Receptor Steric Competition
Properties
To study the biochemical and structural mechanisms underlying
JES6-1 and S4B6 effects, we determined the variable region se-
quences of JES6-1 and S4B6 and expressed them recombi-
nantly in scFv and Fab formats. We separately determined the
crystal structures of the mIL-2:scFv-JES6-1 and mIL-2:Fab-
S4B6 complexes to resolutions of 2.8 and 2.2 A˚, respectively
(Figures S2A and S2B and Table S1), and compared them to
the human IL-2 quaternary complex structure (Figures 2A and
2B; Wang et al., 2005). We observed that JES6-1 binds ventrally
(‘‘underneath’’) mIL-2 as it would be disposed in the signaling
complex, between the IL-2Rb and IL-2Rg interfaces on the cyto-818 Immunity 42, 815–825, May 19, 2015 ª2015 Elsevier Inc.kine, directly occluding both subunits.
Conversely, S4B6 binds dorsally (‘‘on
top’’) of mIL-2, directly occluding the IL-
2Ra subunit (Figure 2C). JES6-1 makes
extensive contacts in the region between
the A helix and the N-terminal end of the
AB loop of mIL-2 through complemen-
tarity-determining regions (CDRs) 2 and
3 of the JES6-1 heavy chain (HC) and
CDRs 1 and 3 of the JES6-1 light chain
(LC) (Figure S2C). In particular, mIL-2 res-
idues Q36 and E37, which correspond to
hIL-2 residues (Q22 andM23) essential tothe IL-2:IL-2Rb and IL-2:IL-2Rg interactions, respectively,
engage in hydrogen bonds with JES6-1 LC CDRs 1 and 3, illus-
trating the basis for steric competition between JES6-1 and both
the IL-2Rb and IL-2Rg subunits. In contrast, S4B6 primarily inter-
acts with IL-2Ra-binding residues in the B and C helices of
mIL-2, through contacts with S4B6 HC CDR3 and LC CDRs 1
and 2 (Figure S2D). Our crystallographic findings are consistent
with recent epitope mapping studies performed for JES6-1
(Rojas et al., 2014) and S4B6 (Rojas et al., 2013).
Anti-Cytokine mAbs Elicit Allosteric Effects on
Cytokine-Receptor Interactions
The structural analysis also revealed allosteric effects of anti-
body binding on IL-2 complex formation that play important roles
in their functional properties. No structure of the mouse IL-2:IL-
2Ra complex has yet been determined to compare with the
mIL-2:JES6-1 complex; however, the human IL-2:IL-2Ra com-
plex structure serves as an accurate model for comparison
Figure 3. JES6-1 Allosterically Obstructs IL-
2Ra Binding to IL-2 via Epitope Distortion
Overlay of the hIL-2 quaternary complex (PDB:
2B5I) with the mIL-2:JES6-1 complex. Surface
depictions of the IL-2Ra (cyan), IL-2Rb (navy), and
IL-2Rg (gold) subunits and the JES6-1 antibody
(blue) and cartoon representations of receptor-
bound hIL-2 (pink) and JES6-1-bound mIL-2 (red)
are shown. An enlargement of the IL-2Ra binding
site is provided at right with key IL-2Ra-interacting
residues in the hIL-2 AB loop and the corre-
sponding JES6-1-bound mIL-2 residues labeled.
Arrows highlight differences between the struc-
tures. Also see Figure S3.because human and mouse IL-2 show a high degree of
sequence and structural conservation in residues that engage
their receptors. Although there is no steric clash between
JES6-1 and IL-2Ra (Figure 2B), key residues that contact IL-
2Ra ‘‘switch’’ conformations upon binding to JES6-1. Super-
position of the hIL-2:hIL-2Ra and mIL-2:JES6-1 interfaces
reveals a large-scale remodeling of the AB loop in the respective
complexes, with major changes in both side chain and main
chain positioning of residues important for both JES6-1 and re-
ceptor binding (Figure 3). More specifically, two mIL-2 residues
(K49 and R52) at the N-terminal end of the AB loop that contact
JES6-1 (Figure S2C) also mediate contacts between hIL-2 (res-
idues K35 and R38) and hIL-2Ra. JES6-1 binding distorts the
entire AB loop of mIL-2, repositioning K49 and K52 as well as
K57 (hIL-2 residue K43) and Y59 (hIL-2 residue Y45) from their
presumed receptor-bound states as seen in the human complex.
Potentially, IL-2Ra engagement is initiated by interaction with
residues K49 and R52 at the N-terminal end of the AB loop
that could, then, progressively ‘‘peel off’’ the cytokine from
JES6-1 in a zipper-like mechanism, ultimately leading to dissoci-
ation of JES6-1 (Figure 3). Once JES6-1 dissociates, the IL-
2Ra-bound cytokine is liberated to recruit IL-2Rb and IL-2Rg
to form the functional signaling complex.
These allosteric changes cannot be explained by differences in
structure between the cytokine species, because the AB loop re-
gion of mIL-2 from the S4B6-bound structure overlays closely
(RMSD = 0.771 A˚ for S4B6 versus 3.15 A˚ RMSD for JES6-1)
with receptor-bound hIL-2 (Figure S3). Moreover, the conforma-
tional flexibility in the AB loop region contrasts with the close
correlation between JES6-1-bound mIL-2 and receptor-bound
hIL-2 in other regions of the structures (RMSD = 3.15 A˚ for AB
loops versus 0.729 A˚ for remainder of structures). Thus, JES6-1
capitalizes on the previously noted malleability of the IL-2Ra
binding site on IL-2 (Wang et al., 2005; Thanos et al., 2003,
2006), and conformational changes are confined locally to this re-
gion of the cytokine. We suggest that JES6-1 binding to one site
allosterically impairs IL-2Ra binding to a non-overlapping site,
and this impaired binding (i.e., lowered affinity for IL-2Ra) rendersImmunity 42, 815–JES6-1-bound IL-2 selective for IL-2Rahi
cells, which express sufficient IL-2Ra to
displace the antibody by mass action
and initiate the exchange mechanism.
Overlaying the IL-2 receptor subunits
with S4B6-bound mIL-2 clearly illustratesdirect occlusion of IL-2Ra binding by the antibody (Figure 2B), to
the extent that S4B6 appears to be a structural mimic of IL-2Ra.
Comparison of the hIL-2:hIL-2Ra and mIL-2:S4B6 interfaces
indicates a striking similarity between these two interactions
(Figure 4A). Both the side chain and main chain positioning of
the AB loop and B helix are highly conserved, particularly for in-
teracting residues that are shared between the structures. Here
again, close examination of the structural effects of S4B6 binding
illuminates an unanticipated conformational consequence of the
antibody on IL-2 engagement of IL-2Rb. We previously noted
that human IL-2 undergoes a slight repositioning of the C helix
after IL-2Ra engagement (Wang et al., 2005) and showed that
this structural change in the cytokine is recapitulated by a variant
of IL-2 (denoted super-2) that exhibits 200-fold higher affinity for
the IL-2Rb subunit than the wild-type cytokine (Levin et al.,
2012). S4B6 engages IL-2 in a similar manner to IL-2Ra, and
we find that the antibody does indeed induce a shift in the C helix
compared to the unbound cytokine, coinciding with the struc-
tures of both IL-2Ra-bound hIL-2 and super-2 (Figures 4B and
S4A). Thus, S4B6 mediates steric blockade but also, to a lesser
extent, allosteric effects, eliciting structural changes distal from
its binding site that could impact IL-2Rb binding. Overlay of the
IL-2Rb subunit from the hIL-2 quaternary complex with the
S4B6-bound mIL-2 also reveals that the antibody might slightly
obstruct accessibility of IL-2Rb through a tangential steric clash
between S4B6 LC CDR1 and domain 1 of IL-2Rb (Figure S4B),
which could partially mitigate the affinity-enhancing effect of
S4B6 binding on the IL-2:IL-2Rb interaction. S4B6-mediated
blockade of IL-2Ra binding together with stabilization of the IL-
2Rb-binding conformation of IL-2 would be expected to promote
proliferation of all T and NK cells bearing IL-2Rb and IL-2Rg,
particularly favoring IL-2Rbhi effector cells, consistent with the
functional activity of this antibody.
Anti-IL-2 Antibodies Exert Distinct Effects on IL-2
Cytokine:Receptor Interactions
To rationalize our structural analysis in the context of biophysical
measurements, we displayed mIL-2 on the surface of yeast and825, May 19, 2015 ª2015 Elsevier Inc. 819
Figure 4. S4B6 Mimics the IL-2Ra Subunit,
Allosterically Enhancing Binding of IL-2Rb
(A) Overlay of hIL-2 (pink) bound to IL-2Ra (cyan),
IL-2Rb (navy), and IL-2Rg (gold) and mIL-2 (light
gray) bound to S4B6 (orange) with detailed views
of the hIL-2:hIL-2Ra (left) and mIL-2:S4B6 (right)
interfaces in the AB loops and B helices of the
cytokines juxtaposed at right. Analogous human
and mouse IL-2 residues implicated in both in-
teractions are labeled.
(B) Superposition of cytokine orientations proximal
to the IL-2Rb binding site for unbound super-2
(PDB: 3QB1, salmon), receptor-bound hIL-2 from
the quaternary complex (PDB: 2B5I,pink), S4B6-
boundmIL-2 (red), and unbound hIL-2 (PDB: 3INK,
green).
Also see Figure S4.characterized antibody-receptor competition. Both JES6-1 and
S4B6 potently blocked the mIL-2:mIL-2Ra interaction and
JES6-1 also blocked the mIL-2:mIL-2Rb interaction. S4B6
partially impaired the mIL-2:mIL-2Rb interaction (Figures 5A
and 5B), accounting for itsmild inhibition of STAT5 signaling (Fig-
ure 1B, top), which presumably resulted from the steric clash be-
tween the antibody and IL-2Rb (Figure S4B). Consistent with our
structural findings, these competition studies demonstrate that
both antibodies impact cytokine engagement of the IL-2Ra
and IL-2Rb subunits.
We probed the kinetics of mIL-2 interactions with its receptor
chains in the absence or presence of the JES6-1 and S4B6 anti-
bodies via surface plasmon resonance (SPR). We immobilized
mIL-2Ra and then flowed over pre-incubated mIL-2:antibody
complexes containing a fixed mIL-2 concentration and variable
concentrations of competitor antibody. The two antibodies ex-
hibited qualitatively different effects on binding: whereas S4B6
completely abrogated binding ofmIL-2, residual cytokine binding
occurred in the presence of JES6-1, even when it was in 40-fold
excess over mIL-2 (Figure 5C), implying that mIL-2 can simulta-
neously, but transiently, engage both JES6-1 and mIL-2Ra pre-
sumably in anexchanging intermediate statewherein JES6-1 ‘‘re-
leases’’ as mIL-2Ra engages a low-affinity binding site. Upon
JES6-1 dissociation, themIL-2Rabinding site onmIL-2 remodels
into the high-affinity state.Accordingly, kinetic profiles of JES6-1-
modulated mIL-2:mIL-2Ra interactions indicated that the anti-
body concurrently decreased the association rate (Kon) and
increased the dissociation rate (Koff) of the mIL-2:mIL-2Ra com-
plex (Figure S5A). In contrast, S4B6 competes with IL-2Ra for
binding to mIL-2 in a classical manner, in that IL-2a has to disen-
gage before S4B6 can accessmIL-2: dissociation of IL-2Ra from
mIL-2 is unaffected by S4B6 (Figure S5C). These distinct modes
of IL-2Ra displacement by JES6-1 and S4B6 reflect their unique
structural properties andare essential to their biological activities.820 Immunity 42, 815–825, May 19, 2015 ª2015 Elsevier Inc.We also analyzed the mIL-2:mIL-2Rb
interaction through SPR studies by im-
mobilizing mIL-2Rb and flowing over
immunocomplexes containing variable
ratios of competitor antibody to mIL-2.
JES6-1 fully blocked mIL-2:mIL-2Rb
interaction whereas S4B6-conjugatedmIL-2 bound to mIL-2Rb (Figure 5D). Kinetic profiles showed
that JES6-1 eliminated binding without impacting Koff, consis-
tent with direct competitive inhibition (Figure S5B), and S4B6
led to an increase in the molecular mass of bound analyte, re-
flecting mIL-2Rb engagement of both the cytokine and antibody
(Figure S5D).
We modified the topology of our binding studies, immobilizing
either JES6-1 or S4B6, saturating the antibody-coated surface
with mIL-2, and subsequently measuring mIL-2Ra or mIL-2Rb
binding to the immobilized mIL-2:antibody complexes. mIL-
2Ra did not bind to the immobilized mIL-2:S4B6 immunocom-
plex (Figures 5E and S5I) but bound to the mIL-2:JES6-1
immunocomplex with 200-fold weaker affinity compared to its
interaction with mIL-2 alone (Figure 5E). The kinetic profile re-
vealed a dramatic increase in the mIL-2Ra Koff in the presence
of JES6-1 (Figures S5E and S5G), reiterating a presumptive ex-
change between receptor and antibody binding to the cytokine.
Steric inhibition precluded binding ofmIL-2Rb to the immobilized
mIL-2:JES6-1 immunocomplex (Figure 5F and S5H) but, inter-
estingly, we observed 6-fold enhancement in the binding of
mIL-2Rb to the mIL-2:S4B6 immunocomplex compared to its
binding to free mIL-2 (Figure 5F). This affinity improvement was
a net consequence of simultaneous decreases in Kon and Koff
for the mIL-2:mIL-2Rb interaction in the presence of S4B6 (Fig-
ures S5F and S5J). The kinetics of this immunocomplex:mIL-
2Rb interaction were rationalized by structural observations,
because the predicted clash between S4B6 and mIL-2Rb
(Figure S4B) would presumably impede accessibility of the
receptor binding site on mIL-2, hampering Kon. However, this
effect might be counteracted by the conformational change in
the mIL-2 C helix induced by S4B6 binding (Figure 4B), which
would be predicted to lower Koff. Indeed, it was found that
super-2 primarily achieves its IL-2Rb affinity enhancement
relative to wild-type IL-2 by decreasing Koff (Levin et al., 2012).
Figure 5. Anti-IL-2 Antibodies and IL-2 Receptor Compete for Cytokine Binding
Yeast surfacemIL-2 competition studies between anti-mIL-2 antibodies (Abs) and saturating concentrations of mIL-2Ra (A) or mIL-2Rb (B) are shown (error bars,
SD). Data are representative of three independent experiments. Half maximal inhibitory concentrations (IC50s) of the antibodies are indicated. Equilibrium surface
plasmon resonance titrations of mIL-2:antibody immunocomplex interactions with immobilized mIL-2Ra (C) or mIL-2Rb (D) and mIL-2Ra (E) or mIL-2Rb (F)
interactions with unbound mIL-2 compared to interactions with immobilized mIL-2:antibody immunocomplexes are presented. Also see Figure S5.Taken together, our competitive binding studies support the
steric and allosteric effects of anti-IL-2 antibodies seen in the
crystal structures, which manifest as biased functional activities
in vivo.
IL-2:JES6-1 Immunocomplex Signaling Feeds Back onto
IL-2Ra Expression to Perpetuate Treg Cell Proliferation
To further explore the mechanistic basis of the JES6-1-medi-
ated Treg cell proliferation bias, we directly compared prolifer-
ation and IL-2Ra expression in five immune cell subsets after
immunocomplex treatment. As anticipated, per cell IL-2Ra
expression and the proportion of IL-2Ra+ cells were substan-
tially higher on Treg cells compared to effector cells and other
subsets (Figures 6A and 6B). Both IL-2Ra surface density and
the percentage of IL-2Ra+ cells in the Treg cell subset (Fig-
ure 6C) and all other subsets (Figures 6A and 6B) increased
in response to IL-2:JES6-1 immunocomplex treatment com-
pared to mIL-2:S4B6 immunocomplex treatment or unbound
mIL-2 treatment. However, the JES6-1-induced rise in receptor
expression corresponded with increased cell proliferation onlyin the Treg cell subset, implying that a threshold amount of
surface IL-2Ra is required to induce proliferation in the pres-
ence of JES6-1 (Figures 6D and 6E). This finding resonates
with our proposed triggered release mechanism, wherein
sufficient amounts of surface IL-2Ra are required to displace
JES6-1 by mass action. Elevation of IL-2Ra expression after
mIL-2:JES6-1 treatment in turn heightens sensitivity to the im-
munocomplex, creating a positive feedback loop that further
biases immune cell homeostasis to favor IL-2Rahi Treg cells
(Figure S6A).
In the case of mIL-2:S4B6 treatment, we found that induced
proliferation did not correlate with surface IL-2Ra quantities,
because the immunocomplex promotes proliferation of all IL-2-
responsive immune subsets, particularly IL-2Ralo but also IL-
2Rbhi effector cell subsets (Figures 6A–6E). This corroborates
our proposed S4B6 mechanism of action, wherein steric
blockade renders IL-2 insensitive to IL-2Ra expression and
allosteric enhancement of IL-2Rb binding directs IL-2’s
effects toward IL-2Rbhi effector cells (Figure S6B). Collectively,
these subset expansion and IL-2Ra profiling studies reveal anImmunity 42, 815–825, May 19, 2015 ª2015 Elsevier Inc. 821
Figure 6. mIL-2:JES6-1 Immunocomplex
Induces Increased IL-2Ra Expression to
Create a Positive Feedback Loop Favoring
IL-2Rahi Cell Signaling
(A) IL-2Ra expression quantification (mean fluo-
rescence intensity, MFI) for five immune cell sub-
sets (Treg, MP CD8+ T, NK, NKT, and gd TCR) in
BALB/c mouse spleens after treatment with mIL-2
or mIL-2:antibody immunocomplex.
(B) Percentage of IL-2Ra+ cells within each im-
mune cell subset in treated mouse spleens.
(C) IL-2Ra expression histograms for Treg cells
isolated from treated mouse spleens. Represen-
tative plots from one mouse per cohort are
presented.
(D) Relative cell expansion (transparent thick bars)
and IL-2Ra expression quantification (solid thin
bars) in treated mouse spleens. Responses for
each treatment cohort are normalized to those of
untreated control mice for each cell subset.
(E) Relative cell expansion (transparent thick bars)
and IL-2Ra+ cell percentage (solid thin bars) in
treated mouse spleens, normalized as in (D). Error
bars indicate SD. Data are representative of two
independent experiments.additional layer through which IL-2-directed antibodies regulate
immune homeostasis by altering transcriptional behavior.
DISCUSSION
Since the discovery that certain anti-IL-2 antibodies evoke selec-
tive immune cell proliferation, there has been a great deal of in-
terest in exploiting these molecules to treat immune diseases.
However, in order to harness their therapeutic potential, it is crit-
ical to understand the mechanistic basis for their activities. Half-
life extension alone cannot explain their effects because different
high-affinity IL-2 antibodies exhibit distinct potentiation profiles.
Therefore, we explored the atomic basis for their IL-2 interac-
tions as a possible explanation. It was previously suggested
that antibody selectivity was achieved by steric blockade of
specific epitopes on the cytokine (Boyman and Sprent, 2012),
but we found the mechanism to be more complex. Based on
our collective structural and functional studies, we propose
that the mechanisms for selective immune cell subset potentia-
tion by JES6-1 and S4B6 are multi-layered but ultimately rooted
in the unique structural properties of each antibody.822 Immunity 42, 815–825, May 19, 2015 ª2015 Elsevier Inc.JES6-1 appears to act through a three-
tiered mechanism that induces IL-2 to
potently and exclusively activate IL-
2Rahi cells, skewing the immune cell bal-
ance to favor Treg cells. The first layer of
IL-2 modulation involves extension of the
cytokine’s in vivo half-life. Complexing
cytokines with antibodies has been used
as a strategy for enhancing activity
through prolonged persistence in the
bloodstream (Finkelman et al., 1993),
and Fc receptor-mediated half-life exten-
sion has been previously shown to benecessary though not sufficient for maximal activity of anti-IL-2
antibody immunocomplexes (Le´tourneau et al., 2010). The sec-
ond layer of the JES6-1 mechanism of action comprises the
combined steric and allosteric effects of antibody binding on
the IL-2 structure. JES6-1 sterically blocked binding of IL-2Rb
and IL-2Rg and also allosterically impeded binding of IL-2Ra to
the cytokine. Allosteric disruption of the mIL-2:mIL-2Ra interac-
tion conferred exquisite sensitivity for Treg cells, as indicated by
the fact that high amounts of IL-2Ra expression were required
to overcome this disruption to allow for IL-2 complex formation
and signal activation. IL-2Ralo effector cells were unresponsive
to mIL-2:JES6-1 immunocomplex treatment because IL-2Rb
and IL-2Rg interactions with the cytokine were occluded and
there were not sufficient quantities of IL-2Ra to displace the anti-
body. The third layer of JES6-1 action consists of IL-2Ra
expression upregulation to create a positive feedback loop that
perpetuated proliferation of IL-2Rahi cells. Increased IL-2Ra
expression after mIL-2:JES6-1 treatment presumably resulted
from a coalescence of two effects: (1) increased IL-2Ra tran-
scription, which has been shown to occur in response to IL-2
signaling (Depper et al., 1985), and (2) selective proliferation of
cells with particularly high surface densities of IL-2Ra. Elevated
IL-2Ra expression resulted in enhanced sensitivity to the
mIL-2:JES6-1 immunocomplex, further heightening selectivity
for IL-2Rahi Treg cell expansion.
An important component to the action of JES6-1 is its mono-
valent affinity for IL-2. The mIL-2:JES6-1 affinity is closely
matched to that of the mIL-2:mIL-2Ra complex, allowing the
antibody to effectively compete with the receptor for access to
mIL-2. A higher-affinity antibody might bind too tightly to the
cytokine and fail to release and enable IL-2 receptor complex
formation. Conversely, a lower-affinity antibody might dissociate
more readily from the cytokine and allow interaction with IL-2Rb
and IL-2Rg on all cell types, diminishing the advantage JES6-1
affords Treg cells. The mIL-2:mIL-2Rb affinity is two orders of
magnitude weaker than that of the mIL-2:JES6-1 interaction,
positioning the antibody in an affinity ‘‘sweet spot’’ that primes
it for IL-2Rahi Treg cell bias.
S4B6 also appears to act through a multiple-tiered mecha-
nism to preferentially direct IL-2 toward potentiation of effector
cells. As with JES6-1, the first layer of S4B6-mediated IL-2
modification occurred through extension of in vivo half-life (Le´-
tourneau et al., 2010). However, because the functional conse-
quences of S4B6 are unique to this antibody, increased half-life
alone cannot account for the biased potentiation it orchestrates.
The second layer of S4B6 action includes the collection of steric
and allosteric structural effects it exerts on mIL-2. S4B6 steri-
cally occluded IL-2Ra binding and mildly obstructed IL-2Rb
binding, but it also allosterically strengthened the mIL-2:mIL-
2Rb interaction by inducing an affinity-enhancing conforma-
tional change in mIL-2. The net result was that sensitivity to
IL-2Ra expression was lost as S4B6-bound mIL-2 signals equiv-
alently through the IL-2 ternary complex on all IL-2-responsive
immune cells, and susceptibility to IL-2 signaling was governed
by IL-2Rb expression. Allosteric enhancement of the IL-2:IL-2Rb
interaction by S4B6 led to increased stimulatory activity that
particularly favored IL-2Rbhi effector cells. It has been estab-
lished that IL-2 signaling induces IL-2Rb upregulation (Siegel
et al., 1987), so we speculate that, analogous to the JES6-1 im-
munocomplex, S4B6 might exerts a third layer of regulation on
mIL-2 activity, initiating a positive feedback cycle for IL-2Rb
expression to further bias stimulation in favor of IL-2Rbhi effector
cells.
The complementary JES6-1 and S4B6 pair of IL-2-targeted
antibodies serves as an archetypal system for exploring the
molecular mechanisms underlying selective immune cell subset
potentiation. Future work could expand upon our findings to
design antibody variants with altered affinities and receptor
subunit competition propensities that accentuate immune cell
biasing effects. One could also envision applying our mecha-
nistic insights to other systems by evolving cytokine- or growth
factor-directed antibodies with desired receptor competitive
properties. Although JES6-1 and S4B6 have limited cross-reac-
tivity with hIL-2 and although IL-2Ra expression in activated
effector T cells is more pervasive in human versus mouse tissues
(Malek, 2008), the structural and biophysical studies we present
illuminate a clear engineering-based path to modify these anti-
bodies so that they can exert analogous effects on hIL-2 and
serve as biased T cell subset-selective potentiating agents for
a wide range of immunotherapeutic objectives.EXPERIMENTAL PROCEDURES
Protein Expression and Purification
mIL-2 was expressed in the periplasm of Escherichia coli cells. hIL-2 and the
mouse and human IL-2 receptor subunits were secreted from a baculovirus
expression system. Sequences for the JES6-1 and S4B6 antibodies were iso-
lated from their respective hybridoma cell lines and used to recombinantly ex-
press scFv and Fab fragments in a baculovirus expression system. Details are
provided in the Supplemental Experimental Procedures.
Cell Lines
Procedures for culturing YT-1 cells and sorting for IL-2Ra expression are
described in the Supplemental Experimental Procedures.
YT-1 Cell STAT5 Phosphorylation Studies
YT-1 or IL-2Ra+ YT-1 cells were stimulated with mIL-2, mIL-2:antibody immu-
nocomplexes, or mIL-2:antibody fragment complexes (2:1 molar ratio of anti-
body or antibody fragment to mIL-2). STAT5 activation was analyzed via flow
cytometry as described previously (Ring et al., 2012). Details are provided in
the Supplemental Experimental Procedures.
Immune Cell Subset Proliferation and Receptor Expression Studies
For relative effector cell:Treg cell proliferation studies (Figure 1C), C57BL/6
mice were injected i.p. with mIL-2 immunocomplexes (2:1 cytokine:antibody
molar ratio) or free mIL-2 on days 1, 2, 3, and 4. For immune cell subset expan-
sion and IL-2Ra profiling studies (Figures 6A–6E), C57BL/6 mice were injected
i.p. with mIL-2 immunocomplexes or free mIL-2 on days 1, 2, and 3. In
both studies, mice were sacrificed on day 5 and spleens were harvested,
homogenized, and analyzed for surface and intracellular markers via flow
cytometry. Cells were profiled and average relative expansion of various im-
mune cell subsets compared to untreated control mice was determined for
each cohort. All experiments were approved by the Animal Welfare Committee
at the Institute of Microbiology of ASCR, v.v.i. Details are described in the Sup-
plemental Experimental Procedures.
Mouse Dextran Sodium Sulfate-Induced Colitis Model
BALB/c mice were injected i.p. either daily for 7 days with PBS, once on day 6
with anti-mIL-2Ra antibody (EXBIO, clone PC61.5), or daily for 7 days with
mIL-2:JES6-1 immunocomplexes (2:1 cytokine:antibody molar ratio). On
day 8, twomice per conditionwere sacrificed to assess spleen Treg cell counts
by flow cytometry. The remaining pretreated mice from each cohort were
administered 3% DSS (MP Biomedicals) in their drinking water beginning on
day 8 to induce colitis. On day 15, disease severity was assessed by a clinical
disease activity index (CDAI) and on day 16, mice were sacrificed for colon
measurement and histological analysis. See Supplemental Experimental Pro-
cedures for details.
Yeast Surface and SPR Affinity Titrations
hIL-2 and mIL-2 were displayed on the surface of yeast as described previ-
ously (Boder andWittrup, 1997; Rao et al., 2004). For SPR studies, biotinylated
human and mouse IL-2 receptors or biotinylated anti-IL-2 antibodies were
immobilized to streptavidin-coated chips and binding of hIL-2 and mIL-2
was analyzed on a Biacore T100 instrument (GE Healthcare). Protocol details
are provided in the Supplemental Experimental Procedures.
Crystallization and Data Collection
PurifiedmIL-2 and JES6-1 scFv ormIL-2 and S4B6 Fabwere complexed over-
night at 4C in the presence of carboxypeptidases-A and B (Sigma), co-eluted
over a Superdex-200 size-exclusion chromatography column, and concen-
trated to >10 mg/ml. mIL-2:JES6-1 scFv crystals were grown in sitting drops
at 22C from 0.1 M Bis-tris propane (pH 6.4), 0.2 M sodium citrate, and 19%
PEG 3350 and flash frozen in liquid nitrogen, cryoprotected with the addition
of 25% 2-methyl-2,4-pentanediol (Sigma). A 2.8 A˚ dataset was collected at
beamline 8-2 at the Advanced Light Source. mIL-2:S4B6 Fab crystals were
grown in sitting drops at 22C from 0.1 M Bis-tris propane (pH 6.5), 0.2 M
sodium fluoride, and 20% PEG 3350 and flash frozen in liquid nitrogen, cryo-
protected with the addition of 25% glycerol (Sigma). A 2.2 A˚ dataset was
collected at beamline 11-1 at the Stanford Synchrotron Radiation Laboratory.Immunity 42, 815–825, May 19, 2015 ª2015 Elsevier Inc. 823
Diffraction data were processed with HKL2000. Crystallographic data collec-
tion and refinement statistics are reported in Table S1.
Structure Determination and Refinement
The mIL-2:JES6-1 scFv and mIL-2:S4B6 Fab complex structures were solved
by molecular replacement using PHASER (McCoy, 2007). For mIL-2, a one-to-
one threaded model of mIL-2 to a human IL-2 structure (PDB: 2B5I) generated
in Phyre (Kelley and Sternberg, 2009) was used, and for the JES6-1 and S4B6
VH and VL domains, multiple-threaded models obtained from the I-TASSER
server (Roy et al., 2010; Zhang, 2008) were used. Models of the S4B6 CH1
and CL domains were obtained from the previously solved structure of a rat
Fab (PDB: 1LK3). Iterative model rebuilding and refinement were performed
with the Phenix software (Adams et al., 2002) and COOT (Crystallographic
Object-Oriented Toolkit) (Emsley and Cowtan, 2004). For initial refinement,
rigid body, coordinate, and real-space refinement were used with individual
atomic displacement parameter refinement. Translation, libration, and screw-
rotation refinement was added in later iterations. Ramachandran and rotamer
analysis were performed with MolProbity (Davis et al., 2007). Electron density
connected to N31 of the JES6-1 VH was modeled as an N-linked GlcNAc2
with a-1,6 and a-1,3 difucosylation of the proximal GlcNAc. Interacting resi-
dues were identified with the protein interfaces, surfaces, and assemblies
(PISA) service at the European Bioinformatics Institute (Krissinel and Henrick,
2007). Structural figures were created with PyMOL (DeLano, 2002).
Yeast Surface and SPR Antibody-Receptor Competitive IL-2 Binding
Assays
For yeast surface competition studies, mIL-2-displaying yeast were incubated
concurrently with saturating concentrations of mIL-2Ra or mIL-2Rb and serial
dilutions of unlabeled competitor antibody and subsequently analyzed for re-
ceptor binding via flow cytometry.
SPR-based competition studies were performed on a Biacore T100 instru-
ment in two different topologies. In one orientation, biotinylated mIL-2Ra or
mIL-2Rb was immobilized to a streptavidin-coated chip and binding of pre-
incubated complexes containing saturating amounts of mIL-2 and serial
dilutions of competitor antibody was evaluated. In the other orientation,
biotinylated antibodies JES6-1 or S4B6 were immobilized to a streptavidin-
coated chip, a saturating amount of mIL-2 was then captured on the immobi-
lized antibodies, and binding of soluble mIL-2Ra or mIL-2Rb was evaluated.
See Supplemental Experimental Procedures for details.
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